⌘K
t
| Date | 26 Apr 2024 |
| Time | 09:51:57 |
| Category | Capital structure |
| ID | 2169M |
The following amendment has been made to the publication of Block Listing Six Monthly Return released on 26/04/24 at 7:00AM under RNS No 1211M.
The figure in the first table under "Equals: Balance under scheme(s) not yet issued/allotted at end of period" is 803,006, not 911,730 as announced.
The figure in the second table under "Equals: Balance under scheme(s) not yet issued/allotted at end of period" is 9,719,257, not 11,777,257 as announced.
All other details remain unchanged.
The full amended text is shown below.
26 April 2024
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Block Listing Six Monthly Return
Avacta Group plc (AIM: AVCT), a life sciences developing innovative, targeted oncology drugs and powerful diagnostics, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
|
Name of applicant: |
Avacta Group plc |
|||
|
Name of scheme: |
EMI scheme |
|||
|
Period of return: |
From: |
28 October 2023 |
|
27 April 2024 |
|
Balance of unallotted securities under scheme(s) from previous return: |
797,922 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
113,808 |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
108,724 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
803,006 |
|||
|
|
|
|
|
|
|
Name of applicant: |
Avacta Group plc |
|||
|
Name of scheme: |
LTIP scheme |
|||
|
Period of return: |
From: |
28 October 2023 |
|
27 April 2024 |
|
Balance of unallotted securities under scheme(s): |
5,277,257 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
6,500,000 |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
2,058,000 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
9,719,257 |
|||
|
|
|
|
|
|
|
Name of contact: |
Tony Gardiner, Company Secretary |
|
Telephone number of contact: |
+ 44 (0) 1904 217070 |
Ends-
For further information from Avacta Group plc, please contact:
|
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer Michael Vinegrad, Group Communications Director
|
Tel: +44 (0) 1904 21 7070 |
|
Stifel Nicolaus Europe Limited (Nomad and Joint Corporate Broker) Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Ben Good
|
Tel: +44 (0) 207 710 7600 |
|
Peel Hunt (Joint Corporate Broker) James Steel / Chris Golden / Patrick Birkholm |
Tel: +44 (0) 207 418 8900
|
|
ICR Consilium (Media and IR) Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji |
About Avacta Group plc - https://www.avacta.com
Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.
Avacta has two divisions focused on therapeutics and diagnostics.
Avacta Therapeutics: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.
Avacta Diagnostics: focused on supporting healthcare professionals and broadening access to diagnostics.
Avacta has two proprietary platforms, pre|CISION™ and Affimer®.
The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumours compared with healthy tissues. The pre|CISION™ platform harnesses this tumour specific protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™ antibody/Affimer® drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.
The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown a dramatic improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.
To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/